SE9500023L - Ways to detect cancer - Google Patents

Ways to detect cancer

Info

Publication number
SE9500023L
SE9500023L SE9500023A SE9500023A SE9500023L SE 9500023 L SE9500023 L SE 9500023L SE 9500023 A SE9500023 A SE 9500023A SE 9500023 A SE9500023 A SE 9500023A SE 9500023 L SE9500023 L SE 9500023L
Authority
SE
Sweden
Prior art keywords
amino
acid sequence
fusion proteins
polypeptides
homologues
Prior art date
Application number
SE9500023A
Other languages
Unknown language ( )
Swedish (sv)
Other versions
SE9500023D0 (en
Inventor
Lars Rydlander
Peter Bjoerklund
Original Assignee
Beki Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9401687A external-priority patent/SE9401687D0/en
Application filed by Beki Ab filed Critical Beki Ab
Priority to SE9500023A priority Critical patent/SE9500023L/en
Publication of SE9500023D0 publication Critical patent/SE9500023D0/en
Priority to JP7529563A priority patent/JPH10500408A/en
Priority to PCT/SE1995/000532 priority patent/WO1995031728A1/en
Priority to EP95920334A priority patent/EP0765479A1/en
Priority to AU25821/95A priority patent/AU2582195A/en
Publication of SE9500023L publication Critical patent/SE9500023L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method of detecting cancer in a patient, in which the amount of protein fragments comprising at least one amino-acid sequence selected from the group consisting of the amino-acid sequence (SEQ ID NO: 1) and homologues thereof, and the amino-acid sequence (SEQ ID NO: 2) and homologues thereof, is measured in a sample of body fluid or suspected cells from said patient, is disclosed. Also, the above polypeptides, fusion proteins, RNA and DNA sequences relevant to the polypeptides and fusion proteins, antibodies raised against the polypeptides, fusion proteins, corresponding antigen-mimicking structures or synthetic antibody-mimicking structures complementary to the pertinent epitopes, and diagnostic kits, are disclosed.
SE9500023A 1994-05-17 1995-01-04 Ways to detect cancer SE9500023L (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE9500023A SE9500023L (en) 1994-05-17 1995-01-04 Ways to detect cancer
JP7529563A JPH10500408A (en) 1994-05-17 1995-05-15 Methods for detecting cancer with fragments of cytokeratin 18 and corresponding antibodies
PCT/SE1995/000532 WO1995031728A1 (en) 1994-05-17 1995-05-15 Method of detecting cancer involving fragments of cytokeratin 18 and corresponding antibodies
EP95920334A EP0765479A1 (en) 1994-05-17 1995-05-15 Method of detecting cancer involving fragments of cytokeratin 18 and corresponding antibodies
AU25821/95A AU2582195A (en) 1994-05-17 1995-05-15 Method of detecting cancer involving fragments of cytokeratin 18 and corresponding antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9401687A SE9401687D0 (en) 1994-05-17 1994-05-17 Method of detecting cancer
SE9500023A SE9500023L (en) 1994-05-17 1995-01-04 Ways to detect cancer

Publications (2)

Publication Number Publication Date
SE9500023D0 SE9500023D0 (en) 1995-01-04
SE9500023L true SE9500023L (en) 1995-11-18

Family

ID=26662055

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9500023A SE9500023L (en) 1994-05-17 1995-01-04 Ways to detect cancer

Country Status (5)

Country Link
EP (1) EP0765479A1 (en)
JP (1) JPH10500408A (en)
AU (1) AU2582195A (en)
SE (1) SE9500023L (en)
WO (1) WO1995031728A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
ATE196652T1 (en) * 1996-01-18 2000-10-15 Aventis Pharma Gmbh IN ARTIFICIAL RECOMBINANT SUBSTRATE RAGG-1 AND NATIVE AGGRECAN TO STUDY THE PROTEOLYTIC ACTION OF 'AGGRECANASE' IN CELL CULTURE SYSTEMS
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6207380B1 (en) 1997-09-15 2001-03-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
WO2001012212A1 (en) * 1999-08-13 2001-02-22 The Brigham And Women's Hospital, Inc. Inhibitors of the lectin complement pathway (lcp) and their use
US20020122791A1 (en) * 2000-12-21 2002-09-05 Nicolette Charles A. Antigenic CK-18 compounds for therapy and diagnosis and methods for using same
AU2003227148A1 (en) * 2002-04-05 2003-10-27 Arius Research, Inc. Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
WO2007076439A2 (en) * 2005-12-22 2007-07-05 Abbott Laboratories Methods and marker combinations for screening for predisposition to lung cancer
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
US7883904B2 (en) 2006-05-19 2011-02-08 The Cleveland Clinic Foundation Detection and monitoring of liver damage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2723203B2 (en) * 1984-01-06 1998-03-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cytokeratin tumor markers and assays for their detection
DE3815932A1 (en) * 1988-01-26 1989-08-03 Progen Biotechnik Gmbh METHOD FOR IDENTIFYING THE ORIGIN OF A CELL TISSUE SAMPLE
DE3923951A1 (en) * 1989-07-19 1991-01-31 Boehringer Mannheim Gmbh METHOD FOR DETECTING LIVER CIRRUS

Also Published As

Publication number Publication date
WO1995031728A1 (en) 1995-11-23
AU2582195A (en) 1995-12-05
JPH10500408A (en) 1998-01-13
SE9500023D0 (en) 1995-01-04
EP0765479A1 (en) 1997-04-02

Similar Documents

Publication Publication Date Title
SE9500023L (en) Ways to detect cancer
CO4870792A1 (en) COMPOUNDS AND SET OF DIAGNOSTIC MEANS TO DETECT AND MONITOR THE PROGRESSION OF CANCER OF PROSTATE
WO1998050554A3 (en) Enterococcus faecalis polynucleotides and polypeptides
TR200000113T2 (en) Compounds to diagnose tuberculosis and methods for using them.
MX9801687A (en) Compounds and methods for diagnosis of tuberculosis.
CA2131826A1 (en) MN Gene and Protein
EP2060630A3 (en) PCA3, PCA3 genes, and methods of use
EP1006182A3 (en) Polypeptide fragments of factor VIIIC, corresponding probes and DNA sequences and DNA constructs
DE60026332D1 (en) DIAGNOSIS OF DOMESTIC SPRUE / CELIAC DISEASE WITH THE HELP OF GLIADINE PITOPENES
WO1997033909A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
DE69638162D1 (en) BINDWEEWEBS GROWTH FACTOR (CTGF)
CA2272845A1 (en) Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
WO1994023030A3 (en) Methods and materials relating to the functional domains of dna binding proteins
DE60043944D1 (en) ZYTOKIN ZCYT018
EP1985705A3 (en) Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections
WO1999047639A3 (en) Staphylococcus aureus genes and polypeptides
EA200000845A1 (en) GENE ENCODING NEW CANCER MARKER
ATE225942T1 (en) PEPTIDE REAGENT FOR DETECTION OF HUMAN CYTOMEGALOVIRUS (CMV)
ATE433463T1 (en) MONOSPECIFIC ANTIBODIES AGAINST FIBRINOGEN AND FIBRINOPEPTIDES B
Heck et al. Isolation, characterization, and amino-terminal amino acid sequence analysis of human neutrophil cathepsin G from normal donors
WO1999018210A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
CA2195385A1 (en) An artificial recombinant substrate (ragg 1) and native aggrecan to study the proteolytic activity of 'aggrecanase' in cell culture systems
DE69734199D1 (en) HUMAN NETRIN-1
CA2174212A1 (en) Assay to detect hcv receptor binding
FR2722508B1 (en) TOXOPLASMA GONDII P30 PROTEIN EXPRESSION CASSETTE

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9500023-8

Format of ref document f/p: F